Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Mutation Analysis of BCR-ABL Tyrosine Kinase Domain In New Chronic Phase-Chronic Myeloid Leukemia Patients with Suboptimal Response or Treatment Failure From Imatinib Treatment.

Dong-Wook Kim, MD, Dongho Kim, Soo-Hyun Kim, Hyun-Gyung Goh, Fabrizio Pane, Timothy Hughes, Jerald P. Radich, Peter Lin, Giuseppe Saglio, Susan Branford, Giovanni Martinelli, Simona Soverini, Andreas Hochhaus

Blood (2010) 116 (21): 3441.

https://doi.org/10.1182/blood.V116.21.3441.3441

Published: 2010

Journal Articles

A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate

Susan Branford, PhD, Hyun-Gyung Goh, Barbara Izzo, Lan Beppu, Christine-Elke Ortmann, Kamila Duniec, PhD, Yu Jin, Richard C. Woodman, MD, Fabrizio Pane, MD, Dong-Wook Kim, Jerald P. Radich, MD, Timothy P. Hughes

Blood (2010) 116 (21): 889.

https://doi.org/10.1182/blood.V116.21.889.889

Published: 2010

Journal Articles

Imatinib Mesylate (IM) Versus IM + Low Dose of Pegylated Interferon Alfa 2a (Peg-IFN 2a) In Newly-Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML).

Luis Antonio Meillon, MD, Salvador Campos-Cabrera, Nancy Delgado-Lopez, Angel A. Fernandez-Martinez, Jesus Medrano-Contreras, Guillermo Gutierrez, MD, Juan F. Perez-Rocha, Eduardo Terreros-Muñoz, Sue C. Gomez-Cortes, Susana Guerrero-Rivera, Kevin A. Nacho-Vargas, MD

Blood (2010) 116 (21): 4497.

https://doi.org/10.1182/blood.V116.21.4497.4497

Published: 2010

Journal Articles

Comparison of Steady-State Imatinib (IM) Trough Levels, Clinical Response, and Safety Between Caucasian and Asian Patients with Chronic Lyeloid Leukemia in Chronic Phase (CML-CP) Treated with 400mg and 800mg Daily Doses of IM in the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) Study.

Dong-Wook Kim, MD, PhD, Camille Granvil, PhD, Eren Demirhan, John Reynolds, Yu Jin, MSc, Yanfeng Wang, PhD, Michele Baccarani, MD, Jorge Cortes-Franco, MD, Brian J. Druker, MD, Timothy P. Hughes, MD, MBBS, François Guilhot, MD

Blood (2009) 114 (22): 1127.

https://doi.org/10.1182/blood.V114.22.1127.1127

Published: 2009

Journal Articles

Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients.

Blood (2009) 114 (22): 2212.

https://doi.org/10.1182/blood.V114.22.2212.2212

Published: 2009

Journal Articles

Identification of Rab5 as a Gene Involved in Chronic Myeloid Leukemia (CML) Progression.

Daniela Cilloni, MD, PhD, Monica Pradotto, PhD, Francesca Messa, PhD, Francesca Arruga, PhD, Enrico Bracco, PhD, Sonia Carturan, PhD, Chiara Maffè, PhD, Emanuela Messa, MD, Antonia Rotolo, MD, Elisabetta Greco, MD, Ilaria Iacobucci, PhD, Thea Kalebic, MD, Roberto Bernardoni, Fabrizio Pane, MD, Giovanni Martinelli, MD, Michele Baccarani, M.D., Giuseppe Saglio, MD

Blood (2009) 114 (22): 3470.

https://doi.org/10.1182/blood.V114.22.3470.3470

Published: 2009

Journal Articles

Quantitative PCR Using a Nanofluidic Platform to Quantify Bcr-Abl mRNA in Patients Who Are Negative by Routine Quantitative PCR Testing.

Vivian G. Oehler, Bret Helton, Thea Kalebic, Jerald P. Radich

Blood (2009) 114 (22): 3300.

https://doi.org/10.1182/blood.V114.22.3300.3300

Published: 2009

Journal Articles

Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity.

Blood (2009) 114 (22): 3283.

https://doi.org/10.1182/blood.V114.22.3283.3283

Published: 2009

Journal Articles

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Michele Baccarani, MD, Brian J. Druker, MD, Jorge Cortes-Franco, MD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD, Fabrizio Pane, Susan Branford, PhD, Yu Jin, MSc, Tillmann Krahnke, PhD, Marc Rudoltz, MD, Jerald P. Radich, MD, François Guilhot, MD

Blood (2009) 114 (22): 337.

https://doi.org/10.1182/blood.V114.22.337.337

Published: 2009

Journal Articles

Disabled Gene Is Involved in CML Progression and Its Expression Level at Diagnosis Can Predict Major Molecular Response (MMR) to Imatinib Therapy.

Daniela Cilloni, MD, PhD, Francesca Arruga, PhD, Francesca Messa, PhD, Monica Pradotto, PhD, Enrico Bracco, PhD, Sonia Carturan, PhD, Chiara Maffè, PhD, Emanuela Messa, MD, Antonia Rotolo, MD, Elisabetta Greco, MD, Ilaria Iacobucci, PhD, Roberto Bernardoni, Fabrizio Pane, MD, Thea Kalebic, MD, Giovanni Martinelli, Michele Baccarani, MD, Giuseppe Saglio, MD

Blood (2009) 114 (22): 3964.

https://doi.org/10.1182/blood.V114.22.3964.3964

Published: 2009

Journal Articles

Imatinib (IM) Pharmacokinetic (PK) Exposure and Its Correlation with Clinical Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) for 400 Mg and 800 Mg Daily Doses (Tyrosine Kinase Dose Optimization Study [TOPS])

François Guilhot, MD, Timothy P Hughes, MD, Jorge Cortes, MD, Yanfeng Wang, PhD, Michael Hayes, PhD, Anthony Gichangi, PhD, Brian J. Druker, MD, Michele Baccarani, MD

Blood (2008) 112 (11): 447.

https://doi.org/10.1182/blood.V112.11.447.447

Published: 2008

Journal Articles

CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study

Deborah L White, PhD, Verity A Saunders, Phuong Dang, Amity Frede, Laura Eadie, Simona Soverini, PhD, Fabrizio Quarantelli, Peter Lin, Mark Thornquist, Dong-Wook Kim, MD, PhD, Fabrizio Pane, MD, Giovanni Martinelli, Jerald Radich, Thea Kalebic, MD, Giuseppe Saglio, MD, Timothy Hughes, MD

Blood (2008) 112 (11): 3187.

https://doi.org/10.1182/blood.V112.11.3187.3187

Published: 2008

Journal Articles

The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial.

Nicola Esposito, PhD, Fabrizio Quarantelli, Luigia Luciano, MD, Barbara Izzo, PhD, Anna Lucia Peluso, PhD, Marco Picardi, MD, Susan Branford, PhD, D.L. White, PhD, Timothy Hughes, PhD, Jerald Radich, Simona Soverini, PhD, Ilaria Iacobucci, PhD, Giuseppe Saglio, MD, Thea Kalebic, PhD, Mark Thornquist, PhD, Giovanni Martinelli, MD, Fabrizio Pane, MD

Blood (2008) 112 (11): 1106.

https://doi.org/10.1182/blood.V112.11.1106.1106

Published: 2008

Journal Articles

Mathematical Simulation of BCR-ABL Real Time Quantitative Polymerase Chain Reaction (RQ-PCR) for Chronic Myeloid Leukemia (CML) Response Monitoring Provides Insight on the Basis of International Standardization.

Vi j ay Modur, MD, PhD, Dean C Bottino, PhD, Susan Branford, PhD, Tillmann Krahnke, PhD, Fabrizio Pane, MD, Marc Rudoltz, MD, Yu Jin, Timothy P Hughes, MD, Dong-Wook Kim, MD, PhD, Jerald Radich, MD, J. Carl Barrett, PhD

Blood (2008) 112 (11): 2124.

https://doi.org/10.1182/blood.V112.11.2124.2124

Published: 2008

Journal Articles

International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM)

Stephen G O’Brien, MD, PhD, François Guilhot, MD, John M Goldman, DM, FRCP, Andreas Hochhaus, MD, Timothy P Hughes, MD, Jerald P. Radich, MD, Marc Rudoltz, MD, Jeiry Filian, Insa Gathmann, M.Sc., Brian J. Druker, MD, Richard A. Larson, MD

Blood (2008) 112 (11): 186.

https://doi.org/10.1182/blood.V112.11.186.186

Published: 2008

NARROW

Mutation Analysis of BCR-ABL Tyrosine Kinase Domain In New Chronic Phase-Chronic Myeloid Leukemia Patients with Suboptimal Response or Treatment Failure From Imatinib Treatment.

A Review of Mutation Analysis In the TOPS Trial of Standard Dose Versus High Dose IM In CML Suggests That Refinements to the ELN Recommendations for Mutation Screening May Be Appropriate

Imatinib Mesylate (IM) Versus IM + Low Dose of Pegylated Interferon Alfa 2a (Peg-IFN 2a) In Newly-Diagnosed Chronic-Phase (CP) Chronic Myeloid Leukemia (CML).

Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients.

Identification of Rab5 as a Gene Involved in Chronic Myeloid Leukemia (CML) Progression.

Quantitative PCR Using a Nanofluidic Platform to Quantify Bcr-Abl mRNA in Patients Who Are Negative by Routine Quantitative PCR Testing.

Association Between Imatinib (IM) Transporters and Metabolizing Enzymes Genotype and Response in Newly Diagnosed Chronic Myeloid Leukemia (CML) Patients (Pts) Is Influenced by Ethnicity.

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Disabled Gene Is Involved in CML Progression and Its Expression Level at Diagnosis Can Predict Major Molecular Response (MMR) to Imatinib Therapy.

Imatinib (IM) Pharmacokinetic (PK) Exposure and Its Correlation with Clinical Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) for 400 Mg and 800 Mg Daily Doses (Tyrosine Kinase Dose Optimization Study [TOPS])

CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study

The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial.

Mathematical Simulation of BCR-ABL Real Time Quantitative Polymerase Chain Reaction (RQ-PCR) for Chronic Myeloid Leukemia (CML) Response Monitoring Provides Insight on the Basis of International Standardization.

International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only